Launch detailed investigations of gene function with engineered transgene expression in mice or rats. Taconic Biosciences' murine genetics experts have successfully generated over 10,000 founder animals, with a >99% success rate creating transgenic mice and rats.
Design constitutive, conditional, and random transgenic animal models to advance your research.
Scale cohorts rapidly with rapid expansion.
Go from gene accession number to transgenic mouse in twelve-to-eighteen weeks.
Taconic's transgenic model generation process employs exclusive cell culture and handling robotics to reduce human error, with strict quality control via PCR genotyping, Southern Blot, and transgene mapping analysis.
Taconic generates targeted transgenic mouse models via site-specific recombination between an exchange vector and the ROSA26 docking site in ES cells.
Insert your murine or human gene of interest without interfering with other gene expression.
Overexpress your gene of interest in a conditional fashion.
Generate only one well-defined founder line.
Achieve high transgene expression levels using the strong CAG promoter.
A conditional version of targeted transgenesis can be generated by the insertion of a CAG promoter and a strong transcriptional termination site, flanked by LoxP sites, 5' to your gene of interest.
Conditional Transgenic Mice
If you work with transgenes that adversely affect mouse development, or need tissue-specific control of transgene expression, consider using conditional transgenic mice in combination with an appropriate Cre-expressing strain.
Random Transgenic Mice
Taconic's custom transgenics program employs pronuclear microinjection technology to generate genetically-modified founder animals.
With pronuclear microinjection, a pre-designed gene (or genes) are injected and randomly integrated into the mouse or rat genome. Multiple transgene copies may be used at the site of insertion to explore gene dosage effects.
Transgenic Mouse Strains
B6SJL (F2 hybrid)
Other strains upon request
Transgenic Rat Strains
Other strains upon request
Cohort Production Package
Taconic's transgenic animal model production package includes:
Documentation and verification of PCR-based genotype protocol by Taconic's Molecular Analysis Department.
Coordinated transfer of donor males to Taconic's breeding facility in Germantown, NY.
Confirmation of genotype of donor males by PCR-based genotyping.
Rapid Expansion using C57BL/6NTac donor females.
Holding of excess donor males until offspring from rapid expansion are weaned.
Initial post-derivation comprehensive health testing (IHMS™-52).
PCR based genotyping of derived offspring.
Holding of derived pups from weaning until ready for shipment (4 weeks) at the Isolator Breeding Solutions facility.
Initial cohort of animals ready for shipment beginning at 5 weeks of age.
Large package 18-20/sex/genotype
Small package 8-10/sex/genotype
Genotypes include heterozygous and wild type
Additional package details:
Package ends when initial cohort is ready for shipping. Post package breeding and fees will be based on your breeding plan.
Package includes initial health testing only; ongoing health testing can be done for an additional charge.
Shipping charges from Taconic to customer are not included in package.
Package assumes receipt of 4 donor males from Taconic, additional services will be charged at catalog prices.
Pricing assumes genetic modification is not sex linked, Mendelian ratios will be obtained, 80% of female breeders will deliver live pups that survive until weaning, and an average litter size of 5 pups. Additional charges may apply if these conditions are not met.
Henderson CJ , McLaren AW1, Wolf CR2. (2014) In vivo regulation of human glutathione transferase GSTP by chemopreventive agents. Cancer Res. 74(16):4378-87.
Bestas B, Moreno PM, Blomberg KE, Mohammad DK, Saleh AF, Sutlu T, Nordin JZ, Guterstam P, Gustafsson MO, Kharazi S, Piątosa B, Roberts TC, Behlke MA, Wood MJ, Gait MJ, Lundin KE, El Andaloussi S, Månsson R, Berglöf A, Wengel J, Smith CI. (2014) Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest. 124(9):4067-81.
Waldschmitt N, Berger E, Rath E, Sartor RB3, Weigmann B, Heikenwalder M, Gerhard M, Janssen KP, Haller D. (2014) C/EBP homologous protein inhibits tissue repair in response to gut injury and is inversely regulated with chronic inflammation. Mucosal Immunol. 7(6):1452-66.
Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH. (2012) LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet. 44(11):1199-206.